Bedrijfsoverzicht
RenovoRx, Inc. is a clinical-stage biopharmaceutical entity dedicated to developing targeted combination therapies designed to improve therapeutic outcomes for cancer patients receiving treatment. The company operates within the healthcare sector, specifically the biotechnology industry, which focuses on the discovery and development of biological substances for the diagnosis, treatment, or prevention of disease. According to available data, the company maintains a market capitalization of $46.59M and employs 17 individuals to execute its strategic objectives. The annual revenue generated over the trailing twelve months stands at $1.12M, indicating a very small operational scale typical of early-stage development firms. This valuation suggests the company is currently valued based on potential future clinical success and intellectual property rather than established cash flow generation, placing it in a high-risk, high-reward position within the biotech landscape where capital efficiency is critical for survival.
Financiële gezondheid
Over the trailing twelve months, RenovoRx reported a revenue of $1.12M alongside a net income of $-11,168,000 and an EBITDA of $-12,008,000. The substantial negative net income relative to the modest revenue stream reveals an aggressive cost structure driven by research and development expenditures common in clinical-stage biotechnology, where significant upfront investment is required before product commercialization. The company generated free cash flow of $-6,420,250, indicating a continuous burn rate that necessitates ongoing capital raising to maintain operations and fund ongoing clinical trials. Profitability metrics are currently non-existent with a profit margin of 0.0%, while the gross margin sits at 70.9%, suggesting the company retains a significant portion of sales revenue before accounting for operating expenses. However, the operating margin is reported at -1269.7%, reflecting the heavy overhead costs associated with R&D and administrative functions that exceed current revenue levels. In terms of leverage, the company holds $7.02M in cash against $212,000 in debt, resulting in a debt-to-equity ratio of 3.91, which indicates a highly leveraged balance sheet relative to its equity base despite the absolute debt amount being low. Liquidity is robust with a current ratio of 4.02, demonstrating that the company possesses ample current assets to cover its short-term liabilities. Return on equity stands at -225.6% and return on assets is -92.6%, metrics that highlight how the company's assets and shareholder equity are currently being utilized to generate losses rather than returns, a standard characteristic for firms in the pre-revenue or early-revenue phases of biotechnology.
Waarderingsbeoordeling
The valuation metrics for RenovoRx reflect its status as a non-profitable entity, evidenced by a trailing P/E ratio (TTM) listed as N/A and a forward P/E of -8.21. The negative forward P/E implies that the market is pricing the stock based on future expectations of earnings recovery or cash flow generation rather than current profitability. The price-to-book ratio is 6.66, which indicates that the market values the company at a significant premium over its book value, likely attributing high value to its intellectual property and clinical pipeline assets. Additionally, the price-to-sales ratio is 41.49 and the EV/EBITDA stands at -3.13, suggesting that investors are willing to pay a high multiple for every dollar of sales despite the lack of earnings, a common practice for clinical-stage assets with promising lead candidates. Regarding price action, the stock has a 52-week high of $1.45 and a 52-week low of $0.70. Without a specific current price provided in the available facts, the trading range demonstrates significant volatility within the last year, with the stock capable of moving between these extremes based on market sentiment regarding clinical trial results. The beta value is 1.22, meaning the stock price is expected to be more volatile than the broader market, amplifying both potential gains and losses relative to the overall index performance.
Growth & Income
The company has demonstrated explosive expansion with a revenue growth rate of 453.5% year-over-year, while earnings growth is listed as N/A due to the company's current lack of net income. The absence of positive earnings growth relative to revenue is expected for a biotechnology firm in development, as revenue scales slowly through partnerships or licensing while expenses remain high. RenovoRx does not distribute dividends, showing a dividend yield of N/A and a payout ratio of 0.0%, which indicates that the company retains all available capital to fund its research and development activities rather than returning value to shareholders. This reinvestment strategy is essential for a clinical-stage company that must preserve cash to progress its lead product candidate, chemotherapy gemcitabine provided through RenovoCath, through clinical trials. The overall growth and income profile is characterized by rapid revenue acceleration coupled with substantial cash burn and no income distribution, reflecting a classic high-growth, pre-profitability capital-intensive business model.